iShares US Healthcare Providers

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

JPMorgan cuts HCA Healthcare price target to $490

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

North Dakota Investment Board Increases CVS Holdings as Q1 Earnings Beat Expectations

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

CVS Health Joins CNCF as Platinum Member to Optimize Tech Architecture

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

UnitedHealth's Optum Rx Introduces New Pharmacy Care Model for Transparency

UnitedHealth Group to Host UHC Medicare Sales Virtual Job Fair

DNB Asset Management Increases CVS Stake by 17.6%, Analysts Upgrade to Buy

Canada Post Corp Registered Pension Plan Increases Stake in UnitedHealth Group

Abacus Wealth Partners Invests $1.23M in Cigna Q4 as Earnings Beat Expectations

UnitedHealth Group Outlines Plan to Cut Medicare Advantage Members to Protect Profitability

UnitedHealth Group Expects to Complete at Least $2 Billion in Share Repurchases by End of Q2

Leuthold Group LLC acquired a new $9.29 million stake in UnitedHealth Group.

UnitedHealth's 2026 Health Trends Report projects an 8.5% increase in medical costs.

Qsemble Capital Management LP Makes New $3.42 Million Investment in UnitedHealth Group

Stephens Inc. AR Purchases 9,617 Shares of UnitedHealth Group

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

MEDP

IDNA

ARKG

A class action lawsuit has been filed against Medpace Holdings Inc. for securities fraud, alleging misrepresentations regarding cancellation rates and book-to-bill ratios, leading to a 16% stock drop. Investors are urged to act by June 8, 2026, to be appointed as lead plaintiffs. The case is pending in the U.S. District Court for the Southern District of Ohio.

prnewswire

Medpace

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

SPDR S&P Health Equip

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares US Medical Devices

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

Tesla

Teva Pharmaceutical Industries

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

UNHG

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

Market Beat

Unitedhealth

SPDR S&P Health

VG Health

Leverage Shares 2X Long UNH Daily ETF

iShares Global Healthcare

Barclays

Jefferies Financial

KeyCorp

Berkshire Hathaway

Berkshire Hathaway B

Thomson Reuters

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB increased its stake in HCA Healthcare, Inc. by 7.9% in Q4, owning 213,272 shares valued at approximately $99.57 million. Other hedge funds also adjusted their positions. HCA's stock opened at $422.60, with a market cap of $93.75 billion. The company reported Q1 earnings of $7.15 per share, slightly below estimates, and announced a quarterly dividend of $0.78. Analysts have varied price targets, with UBS raising theirs to $635.00.

HCA Healthcare

UBS Group AG

Goldman Sachs

Toronto Dominion Bank

ROYAL BANK OF CANADA

GS Hldg R

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

HIMS

HIMZ

Hims & Hers Health has upsized its private offering of 0% convertible senior notes to $350 million, increased from $300 million. The offering, due June 1, 2032, includes a 13-day option for initial purchasers to buy an additional $52.5 million. Proceeds will fund capped call transactions, support the acquisition of Eucalyptus, and cover general corporate purposes. The offering is expected to close Thursday.

Fidelity

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health Prices Upsized $350 Million Notes Offering

BRK.B

BRK.A

Berkshire Hathaway sold its entire stake in UnitedHealth in Q1 2026, leading to a decline in the insurer's stock. CEO Greg Abel's strategy reflects a shift towards quicker trades, contrasting with Warren Buffett's long-term approach. Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

- Berkshire Hathaway divested its entire UnitedHealth position in Q1 2026, leading to a decline in the insurer's stock.  
- CEO Greg Abel is adopting a strategy of quicker trades and capital redeployment, contrasting with Warren Buffett's long-term investment approach.  
- Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

Berkshire's UnitedHealth exit sends shares lower despite turnaround

AMST

Amesite Inc. (NASDAQ:AMST) shares surged 90.82% to $1.50 in after-hours trading following the announcement of its largest enterprise deployment and a 171% year-over-year revenue growth to $83,330. The company secured a new customer for its AI-native NurseMagic platform, aimed at enhancing patient documentation efficiency. Despite this, AMST has seen a 74.06% decline over the past year and closed the regular session at $0.79, down 4.58%. The stock currently trades near its 52-week low.

benzinga_article

Amesite

Taiwan Semiconductor

NVIDIA

NVIDIA Corporation

Amesite (AMST) Stock Is Trending Overnight — Here's Why It Moved Nearly 91% In After-Hours Session

HIMY

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

Unusual Whales

Defiance Leveraged Long +Income HIMS ETF

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

ResMed Inc. (RMD) shares rose 1.12% to $204.15 on Monday, outperforming a mixed stock market session. The Dow Jones increased by 0.32%, while the S&P 500 fell by 0.07%. ResMed's stock remains 30.52% below its 52-week high of $293.81, reached on August 22nd. Trading volume was 1.0 million, below the 50-day average of 1.2 million.

MarketWatch Automated

Resmed

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

Dow Jones Industrial Average

S&P 500

Factset Research

ResMed Inc. Stock Rises Monday, Outperforms Market

IDXX

IDEXX Laboratories Inc. (IDXX) shares rose 3.21% to $545.79 on a mixed trading day, while the Dow Jones increased by 0.32% and the S&P 500 fell by 0.07%. Despite the gain, IDXX remains 29.12% below its 52-week high of $769.98. Competitors like Johnson & Johnson, Medtronic, and Boston Scientific also saw stock increases, with Boston Scientific leading at 6.15%. Trading volume for IDXX was 633,490, surpassing its 50-day average of 559,521.

IDEXX Labs

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Amesite Inc. reported Q3 2026 revenue of $83.33K, a net loss of $678.06K, and diluted EPS of ($0.15), compared to $30.69K revenue and ($0.16) EPS in Q3 2025. Revenue growth for the nine months reached $285.7K, driven by a shift to healthcare markets and the launch of AI-driven NurseMagic™. The company focused on operational efficiency, reducing spending and shifting to monthly service contracts.

TradingView

Amesite Inc. 3Q 2026: Revenue $83.33K, EPS ($0.15) — 10-Q Summary

iShares US Healthcare Providers(IHF.US)

06:13 ETMEDP Deadline Alert: Medpace Investors with Losses are Notified of the Pending Securities Fraud Class Action Over Alleged Misrepresentations

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

Hims & Hers Health Prices Upsized $350 Million Notes Offering

Berkshire's UnitedHealth exit sends shares lower despite turnaround

Amesite (AMST) Stock Is Trending Overnight — Here's Why It Moved Nearly 91% In After-Hours Session

Hims & Hers Health raises $350 million through convertible notes, aimed at supporting global expansion and accelerating AI-driven platform development.

ResMed Inc. Stock Rises Monday, Outperforms Market

IDEXX Laboratories Inc. Stock Outperforms Competitors On Strong Trading Day

Amesite Inc. 3Q 2026: Revenue $83.33K, EPS ($0.15) — 10-Q Summary